Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
Lexicon Pharmaceuticals (LXRX) reported a Q4 loss of $0.09 per share, beating the Zacks Consensus Estimate of a $0.11 loss. This is an improvement from the $0.20 loss per share a year ago.
March 06, 2025 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lexicon Pharmaceuticals reported a Q4 loss of $0.09 per share, which is better than the expected $0.11 loss and an improvement from last year's $0.20 loss.
The better-than-expected earnings report and improvement from the previous year are likely to positively impact LXRX's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100